Market Closed - OTC Markets Other stock markets | 5-day change | 1st Jan Change | ||
0.1705 USD | +0.89% | | +19.23% | +21.79% |
Feb. 15 | Transcript : Elite Pharmaceuticals, Inc., Q3 2024 Earnings Call, Feb 15, 2024 | |
Feb. 14 | Elite Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
Financials (USD)
Sales 2022 | 32.26M | Sales 2023 | 34.16M | Capitalization | 29.4M |
---|---|---|---|---|---|
Net income 2022 | 8M | Net income 2023 | 3M | EV / Sales 2022 | 0.92x |
Net cash position 2022 | 5.75M | Net cash position 2023 | 3.94M | EV / Sales 2023 | 0.75x |
P/E ratio 2022 | 4.73x | P/E ratio 2023 | 9.34x | Employees | 53 |
Yield 2022 * | - | Yield 2023 | - | Free-Float | 77.76% |
More Fundamentals * Assessed data
Chart Elite Pharmaceuticals, Inc.
Dynamic Chart
Latest news about Elite Pharmaceuticals, Inc.
Transcript : Elite Pharmaceuticals, Inc., Q3 2024 Earnings Call, Feb 15, 2024 | ||
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI | |
Elite Pharmaceuticals, Inc. Files ANDA with US FDA to Market Central Nervous System Stimulant | CI | |
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR to Marketing Partner Prasco, LLC | CI | |
Transcript : Elite Pharmaceuticals, Inc., Q2 2024 Earnings Call, Nov 15, 2023 | ||
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 | CI | |
Elite Pharmaceuticals Files Anda with US FDA to Market Opiate Analgesic Product | CI | |
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer | CI | |
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study | CI | |
Transcript : Elite Pharmaceuticals, Inc., Q1 2024 Earnings Call, Aug 15, 2023 | ||
Elite Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 | CI | |
Transcript : Elite Pharmaceuticals, Inc., 2023 Earnings Call, Jun 30, 2023 | ||
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 | CI | |
Elite Pharmaceuticals, Inc Appoints Mark Pellegrino as its Chief Financial Officer | CI | |
Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product | CI |
More news
Latest transcript on Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc., Q3 2024 Earnings Call, Feb 15, 2024
More transcripts
Press releases Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 Ended December 31, 2023 and Provides Conference Call Information | AQ | |
Elite Pharmaceuticals, Inc. To Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024 | AQ | |
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant | AQ | |
Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 Ended September 30, 2023 and Provides Conference Call Information | AQ | |
"Exploring Penny Stocks: Four Watchlist Options" FTRS, ELTP, ENZC, ZOM | AQ |
More press releases
Quotes and Performance
1 day | +0.89% | ||
1 week | +19.23% | ||
Current month | +31.46% | ||
1 month | +28.68% | ||
3 months | +5.18% | ||
6 months | +8.60% | ||
Current year | +21.79% |
More quotes
Highs and lows
1 week
0.15
0.18
1 month
0.12
0.18
Current year
0.12
0.21
1 year
0.03
0.21
3 years
0.02
0.21
5 years
0.02
0.21
10 years
0.02
0.47
More quotes
Managers and Directors - Elite Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Nasrat Hakim CEO | Chief Executive Officer | 63 | 13-07-31 |
Carter Ward DFI | Director of Finance/CFO | 59 | 09-06-30 |
Christopher Dick PSD | President | 69 | 02-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Whitnell BRD | Director/Board Member | 68 | 09-10-22 |
Barry Dash BRD | Director/Board Member | 93 | 05-03-31 |
Davis Caskey BRD | Director/Board Member | 76 | 16-04-27 |
More insiders
Quotes
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 0.1705 | +0.89% | 818,984 |
24-05-23 | 0.169 | +9.81% | 1,314,734 |
24-05-22 | 0.1539 | +2.26% | 638,141 |
24-05-21 | 0.1505 | +1.83% | 374,122 |
24-05-20 | 0.1478 | +3.36% | 889,973 |
Delayed Quote OTC Markets, May 24, 2024 at 03:57 pm EDT
More quotes
Company Profile
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. The Company specializes in developing and manufacturing oral, controlled-release drug products. It owns multiple generic products which has been licensed to Prasco, LLC and TAGI Pharma. The Companyâs segments include Abbreviated New Drug Applications (ANDA) and New Drug Application (NDA). The Companyâs products include Phentermine HCl 37.5mg tablets, Phendimetrazine Tartrate 35mg tablets, Phentermine HCl 15mg and 30mg capsules, Naltrexone HCl 50mg tablets, Trimipramine Maleate Immediate Release 25mg, 50mg and 100mg capsules, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Immediate Release 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg and 30mg tablets, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules and others.
Sector
Pharmaceuticals
Calendar
2024-06-11 - Q4 2024 Earnings Release (Projected)
More about the company
Income Statement Evolution
More financial data
Sector Generic Pharmaceuticals
1st Jan change | Capi. | |
---|---|---|
ELITE PHARMACEUTICALS, INC. | +21.79% | 182M |
SUN PHARMACEUTICAL INDUSTRIES LTD. | +18.04% | 42.95B |
OTSUKA HOLDINGS CO., LTD. | +15.75% | 21.38B |
SANDOZ GROUP AG | +18.33% | 15.05B |
CIPLA LIMITED | +19.27% | 14.45B |
ZYDUS LIFESCIENCES LIMITED | +56.12% | 13.04B |
THE MEDICINES COMPANY | -0.05% | 6.79B |
ONO PHARMACEUTICAL CO., LTD. | -12.92% | 6.72B |
STADA ARZNEIMITTEL | -8.87% | 5.73B |
ASPEN PHARMACARE HOLDINGS LIMITED | +11.21% | 5.47B |
Generic Pharmaceuticals
- Stock Market
- Equities
- ELTP Stock